Semaglutide and Gallbladder: Risks and Symptoms

Semaglutide and gallbladder problems are linked: gallstones and gallbladder inflammation were more common with the medicine than with placebo, an inactive treatment. The numbers were small. In Wegovy's adult injection trials, gallstones were reported in about 16 of every 1,000 people, versus 7 of 1,000 on placebo.

Rapid weight loss contributes, but it doesn't explain the whole increase. Severe upper-belly pain, fever, or yellowing skin needs medical assessment right away, even without much weight loss.

How often semaglutide and gallbladder problems happen

Gallstones are hardened deposits in bile, the digestive fluid stored in the gallbladder. The medical word is cholelithiasis. Cholecystitis means an inflamed gallbladder. They're related problems, but the labels count them separately.

As of September 30, 2026, the day this article was written, the manufacturer labels on DailyMed read “Revised: 6/2026” for Wegovy and “Revised: 5/2026” for Ozempic injection. Both carry an acute gallbladder disease warning, covering sudden gallstone or inflammation problems.

These are the adult injection-trial figures:

The Ozempic doses describe study groups, not a dosing plan. That lower percentage at 1 mg doesn't establish that a higher dose protects the gallbladder.

Wegovy's figures come from weight-management studies; Ozempic's come from diabetes studies. Their different participants and follow-up make a direct risk ranking unreliable. The tablet figures are separate, too: Wegovy's label reports gallstones in 2.5% versus 1% in its adult tablet trial.

What STEP 1 and the newer analysis found

In STEP 1, a 68-week study of 1,961 adults without diabetes, gallbladder-related disorders occurred in 2.6% with semaglutide and 1.2% with placebo. Most were gallstones (Wilding et al., New England Journal of Medicine, 2021). That broader category differs from the gallstones-only label figure. The STEP 1 results explain the rest of the trial.

As of September 30, 2026, the day this article was written, a combined STEP analysis published online July 6, 2026 adds a semaglutide-specific estimate. Ukkonen and colleagues, writing in Diabetes, Obesity and Metabolism, combined four trials involving 3,683 participants.

They reported about two gallbladder events for every 100 people followed for one year, versus about 0.8 with placebo. The relative risk, meaning the risk compared with the other group, was 2.08: roughly double. Its 95% confidence interval, a range expressing statistical uncertainty, was 1.16–3.72.

This wasn't routine scanning for silent stones. It counted reported problems, so it can't show how often stones formed without symptoms. Adding STEP 4 made the estimate smaller and too uncertain to establish an increase. Both groups in that trial had received semaglutide before being assigned to continue or stop it.

Why rapid weight loss raises gallstone risk

The gallbladder stores bile and releases it when food arrives. During fast weight loss, the liver releases extra cholesterol into bile. The gallbladder may also empty less completely, making stones more likely (NIDDK's explanation).

Semaglutide mimics GLP-1, a gut hormone involved in fullness and blood-sugar control. Medicines acting on this pathway may also affect gallbladder emptying. Crucially, Wegovy's label says gallbladder disease remained more common even after accounting for weight loss.

A 2022 review by He and colleagues in JAMA Internal Medicine combined 76 randomized trials, studies assigning treatment by chance, with 103,371 participants. Gallbladder or bile-duct disease was 37% more likely with GLP-1 medicines overall. That's a relative increase, not a 37% chance of developing stones. The increase was larger in weight-loss trials, at higher doses, and with longer treatment.

Would switching to tirzepatide avoid this problem?

Switching doesn't remove the gallbladder discussion. As of September 30, 2026, the day this article was written, the Zepbound label, which reads “Revised: 08/2026”, also carries an acute gallbladder disease warning. Zepbound contains tirzepatide.

The tirzepatide and gallbladder guide covers its figures. Comparing percentages from separate labels cannot establish which medicine is safer for one person's gallbladder. A switch needs its own clinical review.

Semaglutide gallbladder symptoms that need urgent care

Gallbladder pain often sits under the right ribs. It may follow a heavy meal and last for hours. Nausea alone can't identify a gallbladder problem; common semaglutide side effects include nausea for other reasons.

The NIDDK calls for medical care right away when a gallbladder attack includes:

• Belly pain lasting several hours.
• Nausea and vomiting.
• Fever or chills.
• Yellowing skin or eyes.
• Dark urine and unusually pale stools.

Severe pain warrants urgent assessment without waiting for a time threshold. Persistent or severe pain spreading to the back can also signal pancreatitis, inflammation of the pancreas. The semaglutide labels direct treatment to be stopped if pancreatitis is suspected. Semaglutide and pancreatitis explains that separate warning.

Can you take semaglutide without a gallbladder?

Gallbladder removal doesn't automatically rule out semaglutide. Neither manufacturer label lists that surgery as a contraindication, a reason the medicine must not be used. Neither provides a separate risk estimate for people after gallbladder removal, either.

That leaves a personal prescribing decision rather than a blanket reassurance. The reason for surgery, any previous pancreas inflammation, ongoing symptoms, and recovery all give the clinician useful context.

Removal also doesn't eliminate every possible stone problem. MedlinePlus explains that bile-duct stones can occur after gallbladder removal. The bile ducts are the tubes that carry digestive fluid to the intestine. New upper-belly pain still needs assessment after surgery; it isn't automatically an ordinary medication side effect.

What a prescriber does with this history

Previous stones, attacks, scans, and surgery belong in the review before treatment. If symptoms appear during treatment, both gallbladder warnings call for diagnostic testing and clinical follow-up. They don't direct an automatic permanent stop for every gallstone finding. The clinician decides whether treatment continues or pauses while the cause is assessed.

Through Promise, semaglutide is dispensed as a compounded medication, prepared by a pharmacy for a prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that these preparations don't undergo its review for safety, effectiveness, or quality before marketing. Brand-trial percentages cannot establish the risk of Promise's specific preparation.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. A previous gallbladder problem gives that conversation a starting point, not an automatic answer.